Skip to content
10-Q

Quarterly Report

Asterias Biotherapeutics, Inc.

0001140361-18-022510

← back to feed
Filed
May 9, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Capex Q1 2018 · Mar 31, 2018 $0
Capex Q1 2018 · Mar 31, 2017 $14K
Operating Cash Flow Q1 2018 · Mar 31, 2018 −$3.94M
Operating Cash Flow Q1 2018 · Mar 31, 2017 −$7.15M
Cash And Equivalents Q1 2018 · Mar 31, 2018 $10.52M
Cash And Equivalents Q1 2018 · Dec 31, 2017 $13.27M
Cash And Equivalents Q1 2018 · Mar 31, 2017 $18.06M
Cash And Equivalents Q1 2018 · Dec 31, 2016 $19.8M
Stockholders Equity Q1 2018 · Mar 31, 2018 $33M
Stockholders Equity Q1 2018 · Dec 31, 2017 $33.54M
Current Liabilities Q1 2018 · Mar 31, 2018 $1.96M
Current Liabilities Q1 2018 · Dec 31, 2017 $3.52M
Total Liabilities Q1 2018 · Mar 31, 2018 $6.32M
Total Liabilities Q1 2018 · Dec 31, 2017 $9.55M
Current Assets Q1 2018 · Mar 31, 2018 $19.95M
Current Assets Q1 2018 · Dec 31, 2017 $22.72M
Total Assets Q1 2018 · Mar 31, 2018 $39.33M
Total Assets Q1 2018 · Dec 31, 2017 $43.09M
Sga Expense Q1 2018 · Mar 31, 2018 $1.91M
Sga Expense Q1 2018 · Mar 31, 2017 $4.47M
Rd Expense Q1 2018 · Mar 31, 2018 $3.63M
Rd Expense Q1 2018 · Mar 31, 2017 $6.6M
Net Income Q1 2018 · Mar 31, 2018 −$2.31M
Net Income Q1 2018 · Mar 31, 2017 −$6.29M
Operating Income Q1 2018 · Mar 31, 2018 −$5.12M
Operating Income Q1 2018 · Mar 31, 2017 −$9.11M
Gross Profit Q1 2018 · Mar 31, 2018 $415K
Gross Profit Q1 2018 · Mar 31, 2017 $1.96M
Cost Of Revenue Q1 2018 · Mar 31, 2018 $63K
Cost Of Revenue Q1 2018 · Mar 31, 2017 $53K